US FDA approves Otsuka's tolvaptan for hyponatraemia
This article was originally published in Scrip
Executive Summary
The US FDA has approved Otsuka Pharmaceutical's vasopressin V2-receptor antagonist, tolvaptan, for patients with hypervolemic and euvolemic hyponatraemia. The drug, which is the first oral vasopressin antagonist to be approved, will be marketed as SAMSCA.